for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
A new world is possible.
Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
The Google-owned website has attracted millions of new paying users
Still illegal at federal level, industry has to pay high fees for financial services from less well-known firms
Plants gratify our need for beauty and nourishment but also speak to a more ambiguous desire — to alter human consciousness
US seeks talks with World Anti-Doping Agency after suspension of star sprinter Sha’Carri Richardson
Increasing minority ownership is a challenge, even in a nascent industry
From sustainable farming to skincare, cannabis is hitting a new high
Oxford Cannabinoid Technologies emerged from university research project into potential treatments
Hype around legalisation has not turned into reliable profits
Backers of themed ETFs optimistic after rulings by UN and European Court of Justice boost investor sentiment
Tracee Ellis Ross, Dan Levy, Adam Curtis, Dan Pearson, Lisa Brice, Florian Krewer, Simone Ashley and others join a special edition dedicated to the future and finding the positives in life
Craft farming, terroir, tasting notes and appellations is the new language of getting high
Just three prescriptions have been administered by the NHS since 2018, industry reports
Hopes for further liberalisation in the US and beyond spur flurry of dealmaking
State becomes the 16th in the US to allow marijuana sales after lawmakers broker agreement
Case for legalising marijuana is not as straightforward as its advocates say
Maker of Lucky Strike cigarettes moves beyond nicotine in effort to attract consumers
World’s largest marijuana retailer says relaxed attitudes are ‘taking hold’ across continent
Analysis shows 43 out of 59 companies in major marijuana funds were lossmaking
Assets under management by pot-tracking ETFs are at an all-time high.
US group snaps up UK maker of marijuana-based epilepsy drug as sector interest grows
Groups eye IPOs after financial regulator sets out rules for sector
Start-up secures first permit in more than 20 years for commercial cannabis cultivation
Lack of investment-grade companies and questions over legality run counter to optimism
The happy, hazy days of 2018 look a long way away
How to deal with social injustice via the magic of the capital markets, and Jay-Z.